The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

<p>Abstract</p> <p>Background</p> <p>Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir wh...

Full description

Bibliographic Details
Main Authors: Berg Thomas, Däumer Martin, Tappe André, Stürmer Martin, Kaiser Rolf, Walter Hauke, Ehret Robert, Vachta Jan, Wiesmann Frank, Naeth Gudrun, Braun Patrick, Knechten Heribert
Format: Article
Language:English
Published: BMC 2011-02-01
Series:AIDS Research and Therapy
Online Access:http://www.aidsrestherapy.com/content/8/1/7

Internet

http://www.aidsrestherapy.com/content/8/1/7

Similar Items